Skip to main content
Premium Trial:

Request an Annual Quote

MDL Information to Market Partek Informatics Software

NEW YORK, Jan. 14 — Software and informatics firm MDL Information Systems will be the exclusive international marketing partner for Partek Incorporated's life-sciences software, the company said on Monday.

 

The agreement covers Partek's applications for life-sciences data processing, analysis, and visualization. It includes packages for statistical inference, predictive modeling, and programs to link with public and third-party databases.

 

The two companies will also create interfaces between these Partek products and MDL's Integrated Scientific Information System and Assay Explorer data-management systems.

 

Partek Incorporated is a privately held company in St. Louis, Mo. It specializes in statistical and visual pattern recognition software for engineering and life sciences companies, including applications for genomic and proteomic data analysis.

 

MDL Information Systems, based in San Leandro, Calif., is a subsidiary of Elsevier Science.

 

Last month, the company said it will provide software and informatics systems for NiKem Research, the medicinal chemistry spinoff of GlaxoSmithKline's former R&D center in Milan, Italy.

 

NiKem will use MDL's applications in all stages of drug-discovery research, including reagent selection, assay design and biological data capture, storage and analysis, chemical data searching, and chemical registration.

 

NiKem Research, which was formed in August 2001 by former SmithKline Beecham scientists, supplies services and products to the pharmaceutical industry. It is currently focused on lead optimization in pre-clinical drug development.

 

GlaxoSmithKline holds a minority equity stake in the company, and has a two-year contract with NiKem for lead optimization in treatments for neurology and respiratory diseases.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.